The pharmaceutical industry could face a lighter load of False Claims Act (FCA) litigation related to reimbursement support services thanks to an early Christmas present from the US Department of Justice (DoJ).
On Dec
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?